Ginsenoside C

Identification

Name
Ginsenoside C
Accession Number
DB06748
Type
Small Molecule
Groups
Nutraceutical
Description
Not Available
Structure
Thumb
Synonyms
  • ginsenoside Rb2
External IDs
NSC 308878 / NSC-308878
Categories
UNII
N219O0L31C
CAS number
11021-13-9
Weight
Average: 1079.281
Monoisotopic: 1078.592374538
Chemical Formula
C53H90O22
InChI Key
NODILNFGTFIURN-GZPRDHCNSA-N
InChI
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26-,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47-,48-,50-,51+,52+,53-/m0/s1
IUPAC Name
(2S,3R,4S,5S,6R)-2-{[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-{[(1R,2R,5S,7R,10R,11R,14S,15R,16R)-16-hydroxy-2,6,6,10,11-pentamethyl-14-[(2S)-6-methyl-2-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxan-2-yl]oxy}hept-5-en-2-yl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl]oxy}-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ginsenoside C.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ginsenoside C.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Ginsenoside C.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ginsenoside C.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ginsenoside C.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Ginsenoside C.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ginsenoside C.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ginsenoside C.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ginsenoside C.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ginsenoside C.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ginsenoside C.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ginsenoside C.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ginsenoside C.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Ginsenoside C.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ginsenoside C.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ginsenoside C.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ginsenoside C.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ginsenoside C.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ginsenoside C.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6917976
PubChem Substance
99443284
ChemSpider
5293194
ChEBI
77152
ChEMBL
CHEMBL449303

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.784 mg/mLALOGPS
logP-0.02ALOGPS
logP-0.92ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)11.75ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count22ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area357.06 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity260.93 m3·mol-1ChemAxon
Polarizability116.99 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6159
Blood Brain Barrier+0.5773
Caco-2 permeable-0.9066
P-glycoprotein substrateSubstrate0.8843
P-glycoprotein inhibitor IInhibitor0.7261
P-glycoprotein inhibitor IINon-inhibitor0.8102
Renal organic cation transporterNon-inhibitor0.8362
CYP450 2C9 substrateNon-substrate0.8625
CYP450 2D6 substrateNon-substrate0.8748
CYP450 3A4 substrateSubstrate0.7082
CYP450 1A2 substrateNon-inhibitor0.9057
CYP450 2C9 inhibitorNon-inhibitor0.8671
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9036
CYP450 3A4 inhibitorNon-inhibitor0.9502
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9413
Ames testNon AMES toxic0.9373
CarcinogenicityNon-carcinogens0.9607
BiodegradationNot ready biodegradable0.9697
Rat acute toxicity4.0254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9348
hERG inhibition (predictor II)Inhibitor0.6172
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as triterpene saponins. These are glycosylated derivatives of triterpene sapogenins. The sapogenin moiety backbone is usually based on the oleanane, ursane, taraxastane, bauerane, lanostane, lupeol, lupane, dammarane, cycloartane, friedelane, hopane, 9b,19-cyclo-lanostane, cycloartane, or cycloartanol skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Triterpene saponins
Alternative Parents
Triterpenoids / Steroidal glycosides / 12-hydroxysteroids / 14-alpha-methylsteroids / Fatty acyl glycosides of mono- and disaccharides / Alkyl glycosides / Disaccharides / O-glycosyl compounds / Oxanes / Secondary alcohols
show 6 more
Substituents
Triterpene saponin / Triterpenoid / Steroidal glycoside / 12-hydroxysteroid / 14-alpha-methylsteroid / Hydroxysteroid / Steroid / Fatty acyl glycoside / Fatty acyl glycoside of mono- or disaccharide / Alkyl glycoside
show 17 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
beta-D-glucoside, disaccharide derivative, tetracyclic triterpenoid, 12beta-hydroxy steroid, ginsenoside (CHEBI:77152)

Drug created on September 06, 2010 13:50 / Updated on November 09, 2017 03:55